Galapagos NV: Galapagos initiates Phase 3 program with filgotinib in patients with active axial spondyloarthritis

OLINGUITO Phase 3 program in adults with axial spondyloarthritis (AxSpA) to include two parallel studies to investigate the efficacy and safety of filgotinib in patients with active radiographic AxSpA

Related Keywords

Belgium ,Bochum ,Nordrhein Westfalen ,Germany ,Mechelen ,Region Flamande ,United Kingdom ,Ruhr ,Northern Ireland ,Craigavon ,Japan ,Japanese ,Great Britain ,Van Gijsel ,Marieke Vermeersch ,Daniele Dambrosio ,Xenofon Baraliakos ,Elisa Chenailler ,Sandra Cauwenberghs ,European Union ,Linkedin ,Japanese Ministry Of Health ,University Bochum ,Exchange Commission ,European Medicines Agency ,Gilead Sciences Inc ,Twitter ,Percentage Of Participants Achieving Spondyloarthritis International Society ,Axspa Topline ,Ankylosing Spondylitis Disease Activity Score ,Internal Medicine ,Ruhr University Bochum ,Coordinating Investigator ,Danieled Ambrosio ,Therapeutic Area Head ,European Summary ,Product Characteristics ,Great Britain Summary ,Northern Ireland Summary ,Japanese Ministry ,Gilead Sciences ,Annual Report ,Ankylosing Spondylitis ,Der Heijde ,Galapagos ,Nitiates ,Hase ,Program ,Filgotinib ,Patients ,Ctive ,Coaxial ,Spondyloarthritis ,